Market Trends,letter

The FDA has been actively issuing warning letters to entities involved in the compounding of semaglutide and other GLP-1 receptor agonists. These actions, particularly highlighted around November 2025, stem from concerns over misleading marketing, product sourcing, and claims that imply compounded semaglutide is equivalent to FDA-approved medications. This crackdown aims to ensure patient safety and maintain the integrity of drug approvals.

In September 2025, the FDA issued a significant number of warning letters, sending warnings to over 55 online sellers of compounded versions of GLP-1 drugs. This initiative targeted telehealth companies that were making false or misleading claims about their compounded semaglutide and tirzepatide products. The FDA's primary concern is that these compounded drugs are not FDA-approved and should not be presented as such. Companies were accused of implying their products were the same as FDA-approved ones, thereby obscuring crucial information about product sourcing and safety.

One notable instance involved DirectMeds, which received a warning letter in September 2025 regarding its sale of compounded semaglutide and tirzepatide. Similarly, on September 9, 2025, warning letters were issued to Hims & Hers, Eli Lilly, and Novo Nordisk. The FDA's warning letter to Novo Nordisk specifically addressed concerns arising from a post-marketing adverse drug experience inspection conducted at their Plainsboro, NJ site in 2025. Another warning letter to Novo Nordisk Inc. (Ref: 716495) dated September 9, 2025, noted the boxed warning on Ozempic regarding the risk of thyroid C-cell tumors and its contraindications.

The FDA has also issued warnings to telehealth companies for illegal GLP-1 sales, emphasizing that compounded drug products are not FDA-approved. This has led to a significant crackdown on compounding semaglutide and tirzepatide products, with FDA officials accusing some providers of making false or misleading claims. The FDA has warned consumers about using compounded versions of FDA-approved medications, with reports indicating some individuals are overdosing on semaglutide.

The FDA's actions are part of a broader effort to address the boom in GLP-1 compounding. The agency has warned that telehealth companies and other providers are implying that these compounded drugs are approved when they are not. This situation is particularly relevant as the FDA officially removed tirzepatide from the shortage list in December 2024 and semaglutide in February 2025.

In March 2026, the FDA continued its intensified crackdown by issuing another batch of 30 warning letters to telehealth companies for making false and misleading claims about compounded GLP-1 receptor agonist products. This persistent action underscores the FDA's commitment to regulating the market and preventing the dissemination of inaccurate information regarding compounded semaglutide and other related medications. The FDA's warning letter to GLP-1 Solution (Ref: 715883) dated September 9, 2025, is another example of the agency's direct communication regarding these issues. The FDA's stance is that compounded drugs, while potentially having a role, must comply with specific conditions for exemptions under sections 503A and 503B of the Food, Drug, and Cosmetic Act. The agency's focus remains on ensuring that any claims made about compounded semaglutide are truthful and not misleading, especially when compared to FDA-approved alternatives.